PIK3CA and neoplasm: Preclinical and early clinical studies demonstrate that dual inhibition—such as combining MEK and PI3K inhibitors—can induce synergistic apoptosis and tumor regression, particularly in tumors harboring KRAS, BRAF, or PIK3CA mutations.